![Frontiers | MOG-IgG-Associated Optic Neuritis, Encephalitis, and Myelitis: Lessons Learned From Neuromyelitis Optica Spectrum Disorder Frontiers | MOG-IgG-Associated Optic Neuritis, Encephalitis, and Myelitis: Lessons Learned From Neuromyelitis Optica Spectrum Disorder](https://www.frontiersin.org/files/MyHome%20Article%20Library/323689/323689_Thumb_400.jpg)
Frontiers | MOG-IgG-Associated Optic Neuritis, Encephalitis, and Myelitis: Lessons Learned From Neuromyelitis Optica Spectrum Disorder
![Myelin oligodendrocyte glycoprotein antibody-associated disorders: clinical spectrum, diagnostic evaluation, and treatment options Myelin oligodendrocyte glycoprotein antibody-associated disorders: clinical spectrum, diagnostic evaluation, and treatment options](https://www.e-cep.org/upload//thumbnails/cep-2019-01305f1.jpg)
Myelin oligodendrocyte glycoprotein antibody-associated disorders: clinical spectrum, diagnostic evaluation, and treatment options
![Identification of a pathogenic antibody response to native myelin oligodendrocyte glycoprotein in multiple sclerosis | PNAS Identification of a pathogenic antibody response to native myelin oligodendrocyte glycoprotein in multiple sclerosis | PNAS](https://www.pnas.org/cms/10.1073/pnas.0607242103/asset/ceeb886d-532f-42c6-9d5a-a7982f62a762/assets/graphic/zpq0490643790002.jpeg)
Identification of a pathogenic antibody response to native myelin oligodendrocyte glycoprotein in multiple sclerosis | PNAS
![Myelin Oligodendrocyte Glycoprotein Antibody-Associated Myelitis Presenting with Headache | Canadian Journal of Neurological Sciences | Cambridge Core Myelin Oligodendrocyte Glycoprotein Antibody-Associated Myelitis Presenting with Headache | Canadian Journal of Neurological Sciences | Cambridge Core](https://static.cambridge.org/binary/version/id/urn:cambridge.org:id:binary:20211029030249736-0986:S0317167121000287:S0317167121000287_fig2.png?pub-status=live)
Myelin Oligodendrocyte Glycoprotein Antibody-Associated Myelitis Presenting with Headache | Canadian Journal of Neurological Sciences | Cambridge Core
![IJMS | Free Full-Text | Cells to the Rescue: Emerging Cell-Based Treatment Approaches for NMOSD and MOGAD IJMS | Free Full-Text | Cells to the Rescue: Emerging Cell-Based Treatment Approaches for NMOSD and MOGAD](https://www.mdpi.com/ijms/ijms-22-07925/article_deploy/html/images/ijms-22-07925-g001.png)
IJMS | Free Full-Text | Cells to the Rescue: Emerging Cell-Based Treatment Approaches for NMOSD and MOGAD
![Overlapping autoimmune syndrome: A case of concomitant anti-NMDAR encephalitis and myelin oligodendrocyte glycoprotein (MOG) antibody disease - ScienceDirect Overlapping autoimmune syndrome: A case of concomitant anti-NMDAR encephalitis and myelin oligodendrocyte glycoprotein (MOG) antibody disease - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0165572819305442-gr3.jpg)
Overlapping autoimmune syndrome: A case of concomitant anti-NMDAR encephalitis and myelin oligodendrocyte glycoprotein (MOG) antibody disease - ScienceDirect
![Antimyelin Antibodies as a Predictor of Clinically Definite Multiple Sclerosis after a First Demyelinating Event | NEJM Antimyelin Antibodies as a Predictor of Clinically Definite Multiple Sclerosis after a First Demyelinating Event | NEJM](https://www.nejm.org/na101/home/literatum/publisher/mms/journals/content/nejm/2003/nejm_2003.349.issue-2/nejmoa022328/production/images/img_medium/nejmoa022328_t1.jpeg)
Antimyelin Antibodies as a Predictor of Clinically Definite Multiple Sclerosis after a First Demyelinating Event | NEJM
![JCI Insight - Siponimod therapy implicates Th17 cells in a preclinical model of subpial cortical injury JCI Insight - Siponimod therapy implicates Th17 cells in a preclinical model of subpial cortical injury](https://df6sxcketz7bb.cloudfront.net/manuscripts/132000/132522/medium/jci.insight.132522.f3.jpg)
JCI Insight - Siponimod therapy implicates Th17 cells in a preclinical model of subpial cortical injury
![Does MOG Ig-positive AQP4-seronegative opticospinal inflammatory disease justify a diagnosis of NMO spectrum disorder? | Neurology Neuroimmunology & Neuroinflammation Does MOG Ig-positive AQP4-seronegative opticospinal inflammatory disease justify a diagnosis of NMO spectrum disorder? | Neurology Neuroimmunology & Neuroinflammation](https://nn.neurology.org/content/nnn/2/1/e62/F1.large.jpg)
Does MOG Ig-positive AQP4-seronegative opticospinal inflammatory disease justify a diagnosis of NMO spectrum disorder? | Neurology Neuroimmunology & Neuroinflammation
![Frontiers | Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disorders: Toward a New Spectrum of Inflammatory Demyelinating CNS Disorders? Frontiers | Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disorders: Toward a New Spectrum of Inflammatory Demyelinating CNS Disorders?](https://www.frontiersin.org/files/Articles/421928/fimmu-09-02753-HTML/image_m/fimmu-09-02753-g001.jpg)
Frontiers | Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disorders: Toward a New Spectrum of Inflammatory Demyelinating CNS Disorders?
A new technology for increasing therapeutic protein levels in the brain over extended periods | PLOS ONE
![Defining distinct features of anti-MOG antibody associated central nervous system demyelination - Martin S. Weber, Tobias Derfuss, Imke Metz, Wolfgang Brück, 2018 Defining distinct features of anti-MOG antibody associated central nervous system demyelination - Martin S. Weber, Tobias Derfuss, Imke Metz, Wolfgang Brück, 2018](https://journals.sagepub.com/cms/10.1177/1756286418762083/asset/images/large/10.1177_1756286418762083-fig1.jpeg)
Defining distinct features of anti-MOG antibody associated central nervous system demyelination - Martin S. Weber, Tobias Derfuss, Imke Metz, Wolfgang Brück, 2018
![Selective Depletion of Antigen-Specific Antibodies for the Treatment of Demyelinating Disease: Molecular Therapy Selective Depletion of Antigen-Specific Antibodies for the Treatment of Demyelinating Disease: Molecular Therapy](https://www.cell.com/cms/asset/53881dd9-f9cd-4011-b1c6-8a07e579594e/fx1.jpg)
Selective Depletion of Antigen-Specific Antibodies for the Treatment of Demyelinating Disease: Molecular Therapy
![MOG antibody disease: A review of MOG antibody seropositive neuromyelitis optica spectrum disorder - ScienceDirect MOG antibody disease: A review of MOG antibody seropositive neuromyelitis optica spectrum disorder - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S2211034818302360-gr1.jpg)
MOG antibody disease: A review of MOG antibody seropositive neuromyelitis optica spectrum disorder - ScienceDirect
![Myelin oligodendrocyte glycoprotein (MOG) antibody-associated disease: practical considerations | Practical Neurology Myelin oligodendrocyte glycoprotein (MOG) antibody-associated disease: practical considerations | Practical Neurology](https://pn.bmj.com/content/practneurol/19/3/187/F1.large.jpg)
Myelin oligodendrocyte glycoprotein (MOG) antibody-associated disease: practical considerations | Practical Neurology
![Myelin oligodendrocyte glycoprotein (MOG) antibody-associated disease: practical considerations | Practical Neurology Myelin oligodendrocyte glycoprotein (MOG) antibody-associated disease: practical considerations | Practical Neurology](https://pn.bmj.com/content/practneurol/19/3/187/F2.large.jpg)